Quick Facts
Plain-English Summary
The CJC-1295 + Ipamorelin blend is one of the most popular growth hormone secretagogue stacks in peptide research circles. CJC-1295 (used without DAC in this formulation) is a synthetic analogue of growth hormone-releasing hormone (GHRH) that acts on the GHRH receptor in the pituitary to stimulate GH release. Ipamorelin is a selective growth hormone releasing peptide (GHRP) that acts on the ghrelin receptor (GHS-R1a) to amplify pulsatile GH secretion.
The combination targets two distinct receptor pathways involved in GH regulation, producing a more physiological GH pulse than either compound alone. Research interest centres on applications including body composition, sleep quality, recovery, and age-related GH decline.
Individual components have pharmacodynamic data in humans, but no randomised controlled trial has studied the specific combination for body composition or anti-ageing endpoints in healthy adults. The synergy argument is pharmacologically sound but clinically unverified.
The absence of DAC (Drug Affinity Complex) in the CJC-1295 component means this formulation produces a shorter-acting, pulse-like GH release pattern rather than the extended GH elevation seen with CJC-1295 with DAC. This is considered more physiological and is the preferred formulation for pre-sleep or pre-exercise dosing protocols in research communities.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Rodent GH pulse studies | Dose-dependent GH elevation with GHRH analogues and GHRPs independently and in combination. Combined administration produces larger and more sustained GH peaks than either agent alone. | Preclinical |
| Primate pharmacodynamics | CJC-class peptides confirmed to produce pulsatile GH release patterns in non-human primates consistent with physiological GHRH stimulation. Teichman et al. 2006 ↗ | Preclinical |
| Ipamorelin selectivity (rat) | Ipamorelin demonstrated highly selective GH release with minimal ACTH/cortisol stimulation compared to GHRP-2 and GHRP-6 at equivalent doses. Selectivity profile well established across multiple rodent models. Raun et al. 1998 ↗ | Preclinical |
| IGF-1 elevation (rodent) | Secondary IGF-1 elevations following GH increases observed in multiple species across GHRH analogue and GHRP studies. IGF-1 rise correlates with dose and GH pulse magnitude. | Preclinical |
| Body composition (rodent) | Chronic GHRP administration associated with lean mass preservation and modest fat mass reduction in aged rodent models. No specific blend RCT data in animals. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| CJC-1295 with DAC — Phase II | 65 healthy adults; dose-escalation pharmacodynamic study | — | Partial |
| Ipamorelin — Postoperative Ileus | Clinical programme conducted by Helsinn Healthcare; healthy volunteer and patient cohorts | — | Partial |
| CJC-1295 + Ipamorelin Blend | — | — | No RCT |
CJC-1295 + Ipamorelin has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
Both CJC-1295 and Ipamorelin were generally well tolerated in their respective clinical studies. No serious adverse events have been attributed to this combination in research settings. Ipamorelin's selectivity makes it preferable to older GHRPs for minimising off-target effects.
Long-term GH elevation raises theoretical concerns about insulin resistance and IGF-1-associated risks, consistent with any GH-augmenting therapy. Chronically elevated IGF-1 has been associated with theoretical cancer-risk in epidemiological literature. No safety data exists for long-term use of this combination in research subjects.
- Transient flushing and tingling at injection
- Mild water retention in early weeks of use
- Transient headache — first days of use
- Increased appetite (less common than with GHRP-2/6)
- Vivid dreams or improved sleep quality reported
- Active or suspected malignancy
- Insulin resistance or diabetes (monitor HOMA-IR)
- Pregnancy or breastfeeding
- Acromegaly or pituitary disorders
- Children and adolescents
CJC-1295 + Ipamorelin is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of CJC-1295 + Ipamorelin for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
6 months on CJC/Ipa at 300mcg each before bed. Measurable IGF-1 increase (+65 points), improved sleep quality (Oura ring confirms), and leaner at same bodyweight. Bloodwork normal throughout. This is the most evidence-supported peptide stack I've used.
IGF-1 response is the right metric to track. What was your baseline and follow-up timing?
The sleep improvement is real and consistent across everyone I know using this. Deep sleep increases noticeably within 2 weeks. Whether it's GH-mediated or something else, the effect is there.
Important to note: the human data is for individual components, not the blend. The synergy argument is pharmacologically sound but clinically unverified. Also worth tracking IGF-1 — chronically elevated levels have theoretical long-term risks.
Fully agree on monitoring. I get quarterly IGF-1, HOMA-IR, and GH panels. So far nothing concerning.
The dual-receptor mechanism is genuinely interesting science. GHRH + ghrelin co-stimulation is how physiological GH pulses work. This stack mimics that more faithfully than either compound alone.